SCM
GYRE icon

Silverarc Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Silverarc Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,333
Closed -$41K – 82
2021
Q3 		$41K Buy
+1,333
New +$43.9K 0.02% 81

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Silverarc Capital Management's GYRE Position: Q4 2021 in Review

Silverarc Capital Management sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 1,333 shares — an estimated $41K sold.

Silverarc Capital Management first reported a position in GYRE in Q3 2021 and held it in 1 quarter. The position peaked at $41K in Q3 2021. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

  • Silverarc Capital Management reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 1,333 Gyre Therapeutics shares in Q4 2021, an estimated $41K.
  • Silverarc Capital Management first reported a position in Gyre Therapeutics in Q3 2021 and held it in 1 quarter.
  • Silverarc Capital Management's Gyre Therapeutics position peaked at $41K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on Silverarc Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.